WALTHAM, Mass • 2023-11-13

BostonGene to Showcase AI-Driven Molecular Profiling Solutions at the Association for Molecular Pathology 2023 Annual Meeting

5 min to read

Workshop Presentation to Highlight the Potential of AI-Driven Molecular Profiling in Tumors

Poster Presentation Unveils Advancements in Genomic Reference Standards for Validating WES Assays

WALTHAM, Mass - November 13, 2023BostonGene, a leading provider of AI-driven molecular and immune profiling solutions today announced that an abstract has been accepted as a poster presentation for the Association for Molecular Pathology (AMP) 2023 Annual Meeting & Expo, which will be held November 14 - 18, 2023, at the Salt Palace Convention Center in Salt Lake City, UT.  During the event, BostonGene will also deliver a presentation at the AMP Corporate Workshop day and exhibit at booth 1301.

Details of BostonGene’s presence at AMP are below:


Title: Unraveling Tumor Profiles Using an HRD-Enabled CGP Assay and Exome Sequencing with AI-Driven Data Analysis
Date and Time: Wednesday, November 15 | 2:00 PM
Location: 255EF, Second Level
Speaker: Katerina Nuzhdina, R&D, Head of Bioinformatics Pipelines Clinical Integration Division, BostonGene

Tumor molecular characterization is key for advancing precision oncology.  In collaboration with Agilent, BostonGene will present its method for detecting somatic variants from cancer samples, enabling large-scale data analyses. The approach combines whole exome sequencing based on Agilent SureSelect technology with BostonGene’s AI-driven best-in-class analytics to identify SNVs, indels, CNAs, TMB, MSI, HRD, and translocations.

Poster Presentation

Title: Developing Bespoke Genomic Reference Standards for Validating Somatic Mutation Detection in Clinical Whole Exome Sequencing Assays
Date and Time: Friday, November 17 | 9:15 AM – 10:15 AM
Location:  Salt Palace Convention Center
Presenter: Anastasiya Yudina, BostonGene

With the increasing use of whole exome sequencing (WES) in precision oncology on FFPE tumor samples, the establishment of robust validation procedures to ensure accurate and reliable WES assay results is necessary. While germline variant calling reference standards are common, reference standards for somatic variant calling require optimization to be used for WES assay validation at the exome-wide level. To address these challenges, BostonGene developed a method for obtaining reference standards and established optimal thresholds for accurate somatic mutation calling in FFPE samples.

Please visit the AMP 2023 Annual Meeting & Expo website for more information. Abstracts are also published in the online-only supplement to the Journal of Molecular Diagnostics.

About BostonGene Corporation

BostonGene is a company at the intersection of technology and biology, dedicated to advancing and personalizing cancer medicine. Founded in 2015, BostonGene has continually pushed the boundaries of innovation to improve cancer patient care and accelerate research and drug development through cutting-edge solutions. Leveraging our AI-powered multiomics platform, we digitize and comprehensively analyze the molecular profiles of cancer patients, including the immune system and tumor microenvironment. Our software solutions, indication-specific cancer library and advanced bioanalytics, enable us to discover multiparametric signatures, identify targets, match them to relevant indications for biopharma and recommend the most effective treatments for patients. For more information, visit www.BostonGene.com.

Erin O’Reilly

Senior Director